Du är här

2015-09-22

ObsEva SA: ObsEva Appoints Elke Bestel as Chief Medical Officer and Jean-Pierre Gotteland as Chief Scientific Officer

ObsEva SA / ObsEva Appoints Elke Bestel as Chief Medical Officer and
Jean-Pierre Gottelandas Chief Scientific Officer . Processed and transmitted
by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
Geneva, Switzerland, 22 September 2015 - ObsEva
, a Swiss biopharmaceutical company developing a novel generation of drugs
addressing serious conditions compromising pregnancy from conception to
birth, announced today new appointments to its Management Team.

Elke Bestel joins ObsEva as Chief Medical Officer&Head of Pharmacovigilance
bringing 19 years of experience in pharmaceutical product development.

Prior to joining ObsEva, Elke was the CMO at PregLem, a Swiss based specialty
biopharmaceutical company. She was one of the key players in the successful
development and European registration of Esmya® (treatment of uterine
fibroids). Prior to PregLem, she worked for Galderma, France, where she was
responsible for clinical studies as well as development, registration and
life-cycle activities of dermatological products (Epiduo®, Soolantra®,
Adapalene® and Clindagel®). Before joining Galderma, she worked at the
clinical research organization MDS, France where she was responsible for the
conduct of clinical studies from Phase I to III.

Elke holds a MD degree from the University of Göttingen, Germany, and received
training in gynecology at the Kantonsspital Bruderholz, Switzerland.

Jean-Pierre Gotteland joins ObsEva as Chief Scientific Officer. He has over 20
years' experience in the pharmaceutical industry in all product development
stages particularly in research, preclinical development and early clinical
development.

After an early career at Pierre Fabre Medicament (France), Jean-Pierre joined
Serono in 1998 (subsequently Merck Serono) where he was responsible for
various research and preclinical development programs in the areas of
neurology, autoimmune disorders, endocrinology, metabolism and oncology. In
2007, he was one of the first employees to join PregLem, a Swiss based
specialty biopharmaceutical company. As VP Non Clinical Development&CMC then
Chief Development Officer, he actively contributed to the successful European
registration of Esmya® (treatment of uterine fibroids), PregLem's lead
product as well as to the progression of development of product portfolio.

Jean-Pierre holds a PhD in Organic Chemistry from the University Claude
Bernard (Lyon, France) and an Engineering Diploma from Ecole Superieure de
Chimie Industrielle (Lyon, France). He was a postdoctoral fellow at the
University of Berkeley (California, USA), and he is the author and co-author
of more than 40 publications and 30 patents.

"I am delighted to welcome Elke and Jean-Pierre at ObsEva, as I had the
opportunity to extensively witness their drug development experience and
capacity at PregLem. It is also very timely as ObsEva is actively enlarging
its portfolio of products in development"
stated Ernest Loumaye, CEO and Co-Founder of ObsEva.

- ends -

About ObsEva

ObsEva is a clinical stage biopharmaceutical company focusing on the
development of a novel generation of drugs addressing serious conditions
compromising pregnancy from conception to birth. Our lead programs target the
underserved problems of infertility and preterm labor affecting more and more
women worldwide. The ObsEva team's unique development expertise is supported
by top-tier investors in order to build a leading company in pregnancy
pharmaceuticals.www.ObsEva.com

For more information, please visitwww.ObsEva.com

For further information, please contact ObsEva CEO Office:
Delphine Renaud
Tel: +41 22 552 1550
Email:delphine.renaud@obseva.ch

Press release (PDF)
http://hugin.info/157613/R/1953402/710833.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ObsEva SA via Globenewswire

HUG#1953402

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.